Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2019 Feb 27

PMID 30804731

Citations 12

Authors

Woo-Shik Kim

Hyun Soo Kim

Jinho Shin

Jong Chun Park

Han-Wook Yoo

Toshihiro Takenaka

Chuwa Tei

Affiliations

Soon will be listed here.

Abstract

Background: Fabry disease is an X-linked recessive disorder caused by deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A). Previous studies identified many cases of Fabry disease among men with left ventricular hypertrophy (LVH). The purpose of this study was to define the frequency of Fabry disease among Korean men with LVH.

Methods: In this national prospective multicenter study, we screened Fabry disease in men with LVH on echocardiography. The criterion for LVH diagnosis was a maximum LV wall thickness 13 mm or greater. We screened 988 men with LVH for plasma α-Gal A activity. In patients with low α-Gal A activity (< 3 nmol/hr/mL), we searched for mutations in the α-galactosidase gene.

Results: In seven men, α-Gal A activity was low. Three had previously identified mutations; Gly328Arg, Arg301Gln, and His46Arg. Two unrelated men had the E66Q variant associated with functional polymorphism. In two patients, we did not detect mutations, although α-Gal A activity was low on repeated assessment.

Conclusion: We identified three patients (0.3%) with Fabry disease among unselected Korean men with LVH. Although the prevalence of Fabry disease was low in our study, early treatment of Fabry disease can result in a good prognosis. Therefore, in men with unexplained LVH, differential diagnosis of Fabry disease should be considered.

Citing Articles

Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM).

Lau K, Sokalski V, Lorenz L, Fette G, Sommer C, Uceyler N Open Heart. 2025; 12(1.

PMID: 39800432 PMC: 11751941. DOI: 10.1136/openhrt-2024-003116.

Role of Genetic Testing in Diagnosis and Prognosis Prediction in Hypertrophic Cardiomyopathy in Korea.

Gwak S, Seo J, Seo G, Oh J, Lee H, Kim K J Korean Med Sci. 2025; 39(50):e313.

PMID: 39742874 PMC: 11685281. DOI: 10.3346/jkms.2024.39.e313.

Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study.

Lin Z, Zhang X, Liu Y, Miao D, Zhang H, Zhang T ESC Heart Fail. 2024; 11(6):4381-4389.

PMID: 39225306 PMC: 11631229. DOI: 10.1002/ehf2.15065.

The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy.

Leung S, Dougherty S, Zhang X, Kam K, Chi W, Chan J J Clin Med. 2024; 13(13).

PMID: 38999464 PMC: 11242528. DOI: 10.3390/jcm13133896.

Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea.

Cho E, Park J, Yoo T, Kim S, Park C, Han S Kidney Res Clin Pract. 2024; 43(1):71-81.

PMID: 38213034 PMC: 10846989. DOI: 10.23876/j.krcp.22.087.

References

Eng C, Guffon N, Wilcox W, Germain D, Lee P, Waldek S . Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001; 345(1):9-16. DOI: 10.1056/NEJM200107053450102. View

Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna W . Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002; 105(12):1407-11. DOI: 10.1161/01.cir.0000012626.81324.38. View

Ommen S, Nishimura R, Edwards W . Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?. Heart. 2003; 89(8):929-30. PMC: 1767790. DOI: 10.1136/heart.89.8.929. View

MCNARY W, LOWENSTEIN L . A MORPHOLOGICAL STUDY OF THE RENAL LESION IN ANGIOKERATOMA CORPORIS DIFFUSUM UNIVERSALE (FABRY'S DISEASE). J Urol. 1965; 93:641-8. DOI: 10.1016/S0022-5347(17)63848-5. View

Yasuda M, Shabbeer J, Benson S, Maire I, Burnett R, Desnick R . Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat. 2003; 22(6):486-92. DOI: 10.1002/humu.10275. View

Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo M . Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004; 110(9):1047-53. DOI: 10.1161/01.CIR.0000139847.74101.03. View

Arad M, Maron B, Gorham J, Johnson Jr W, Saul J, Perez-Atayde A . Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005; 352(4):362-72. DOI: 10.1056/NEJMoa033349. View

Morita H, Larson M, Barr S, Vasan R, ODonnell C, Hirschhorn J . Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation. 2006; 113(23):2697-705. DOI: 10.1161/CIRCULATIONAHA.105.593558. View

Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H . High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006; 79(1):31-40. PMC: 1474133. DOI: 10.1086/504601. View

10.

Monserrat L, Gimeno-Blanes J, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I . Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007; 50(25):2399-403. DOI: 10.1016/j.jacc.2007.06.062. View

11.

Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S . Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009; 119(4):524-9. DOI: 10.1161/CIRCULATIONAHA.108.794529. View

12.

Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen P . Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail. 2010; 12(6):535-40. DOI: 10.1093/eurjhf/hfq073. View

13.

Hagege A, Caudron E, Damy T, Roudaut R, Millaire A, Etchecopar-Chevreuil C . Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study. Heart. 2010; 97(2):131-6. DOI: 10.1136/hrt.2010.200188. View

14.

Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta A . Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart. 2011; 97(23):1957-60. DOI: 10.1136/heartjnl-2011-300364. View

15.

Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, Saito S . Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. Mol Genet Metab. 2012; 105(4):615-20. DOI: 10.1016/j.ymgme.2012.01.010. View

16.

Yousef Z, Elliott P, Cecchi F, Escoubet B, Linhart A, Monserrat L . Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2012; 34(11):802-8. PMC: 3596758. DOI: 10.1093/eurheartj/ehs166. View

17.

Terryn W, Deschoenmakere G, De Keyser J, Meersseman W, Van Biesen W, Wuyts B . Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol. 2012; 167(6):2555-60. DOI: 10.1016/j.ijcard.2012.06.069. View

18.

Mawatari K, Yasukawa H, Oba T, Nagata T, Togawa T, Tsukimura T . Screening for Fabry disease in patients with left ventricular hypertrophy. Int J Cardiol. 2012; 167(3):1059-61. DOI: 10.1016/j.ijcard.2012.10.076. View

19.

Palecek T, Honzikova J, Poupetova H, Vlaskova H, Kuchynka P, Golan L . Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis. 2013; 37(3):455-60. DOI: 10.1007/s10545-013-9659-2. View

20.

Herrera J, Miranda C . Prevalence of Fabry's disease within hemodialysis patients in Spain. Clin Nephrol. 2013; 81(2):112-20. DOI: 10.5414/CN108053. View